CERT
$6.63
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Recent News
Is Certara (CERT) Offering Opportunity After Prolonged Share Price Weakness
If you are looking at Certara and wondering whether the recent share price offers value or just more risk, you are not alone. The stock closed at US$6.65, with a 7 day return of a 5.8% decline, a 30 day return of 0.5%, and longer term returns of a 23.9% decline year to date and a 39.1% decline over 1 year, widening to a 70.3% decline over 3 years and a 78.5% decline over 5 years. These moves have played out against a backdrop of ongoing attention on Certara's position in the healthcare and...
Certara Conference: 2025 revenue hits guidance, EBITDA margin tops range as Q4 software bookings slip
Certara (NASDAQ:CERT) closed 2025 with results that Chief Financial Officer John Gallagher described as strong on revenue and profitability, while acknowledging mixed bookings trends and continued lumpiness in services demand. Speaking with analyst Luke Sergott at a company event, Gallagher said the
Certara Details 2026 Outlook at Leerink Conference as Software Bookings Slow, AI Push Builds
Certara (NASDAQ:CERT) executives used a discussion at the Leerink Partners global healthcare conference to outline recent performance, the assumptions behind the company’s outlook, and the priorities under new CEO Jon Resnick. Chief Financial Officer John E. Gallagher III said the company was please
Certara CEO Resnick Teases Regulatory Services Decision, Phoenix Cloud Push at TD Cowen Conference
Certara (NASDAQ:CERT) executives used a fireside chat at the TD Cowen Health Care Conference to outline early priorities under new CEO Jon Resnick, discuss the company’s ongoing strategic review of its Regulatory Services business, and provide additional context on recent guidance and product moment
Assessing Certara (CERT) Valuation After Recent Share Price Volatility
Event context and recent share performance Certara (CERT) has been drawing investor attention after recent share price swings, including a move of about 4.1% over the past day and close to 9.6% over the past week. Those shorter term gains sit against weaker recent performance, with the stock showing about a 19% decline over the past month and around a 20% decline over the past 3 months, which may prompt investors to reassess expectations. See our latest analysis for Certara. At a share price...